OraSure Technologies Announces 2022 Annual Meeting Date
OraSure Technologies, Inc. (NASDAQ: OSUR) has announced that its 2022 Annual Meeting of Stockholders will take place on May 17, 2022, at 10:00 a.m. EDT, with a record date of March 27, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OraSure Technologies, Inc. (NASDAQ: OSUR) has announced that its 2022 Annual Meeting of Stockholders will take place on May 17, 2022, at 10:00 a.m. EDT, with a record date of March 27, 2022. The meeting will be conducted virtually via a live webcast, allowing only stockholders of record to vote. Additional details will be provided later. OraSure Technologies specializes in rapid diagnostic tests, sample collection, and molecular services, serving various sectors globally, including clinical laboratories and public health organizations.
Positive
- Scheduled Annual Meeting for stakeholders promotes transparency.
- Virtual format allows greater accessibility for stockholders.
Negative
- None.
Details
News Market Reaction – OSUR
The recorded move for OSUR in the trading session of this news was +0.57%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BETHLEHEM, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2022 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 17, 2022. The record date for the Meeting will be March 27, 2022. Only stockholders of record as of the close of business on the record date will be entitled to vote at the 2022 Annual Meeting, or any adjournment(s) or postponement(s) of the Meeting. This will be a completely virtual meeting, conducted as a live webcast. Further details regarding the Meeting will be provided at a later date.
About OraSure Technologies
OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.
For more information on OraSure Technologies, please visit www.orasure.com.
| Investor Contact: Scott Gleason Interim CFO, SVP Investor Relations & Corporate Communications 484-425-0588 sgleason@orasure.com | Media Contact: Amy Koch Senior Manager Corporate Communications 484-523-1815 media@orasure.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.